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A new series of benzothiazole linked isoxazole Schiff base derivatives have been prepared and characterized by 
suitable spectroscopic methods via 1H and 13C NMR, ESI-MS and IR spectra. These compounds have been further screened 
for their antimicrobial activity against a panel of microorganisms. Among them, compounds 12d, 12g and 12l demonstrate 
promising antimicrobial activity against all the tested strains with MIC values ranging between 3.9 – 62.5 µg/mL. Further, 
compounds 12d, 12g and 12l exhibit promising antifungal activity with MIC values ranging between 7.8 – 32.5 µg/mL. 
Further studies are underway for determining the antifungal molecular mechanisms of these potential compounds. 
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Infectious diseases in mankind are becoming ever more 
challenging, primarily in the midst of multidrug 
resistance against the accessible antimicrobial drugs 
ensuing decreased effectiveness
1
. Further, Persistent 
fungal infections pretense an incessant as well as serious 
threat to individual’s wellbeing and existence. Clinically, 
Candidiasis, Aspergillosis and Cryptococcosis are three 
most imperative fungal infections in immuno-
compromised patients
2
. Recently, the rising morbidity 
and appearance of drug-resistance in life threatening 
fungal infections masquerade a momentous health 




Isoxazole containing compounds exhibit diverse 
pharmacological properties such as anti-TB, antiviral, 
anti-proliferative, anti-inflammatory, antibacterial, 
antifungal activities, etc.
4-11 
Risperidone, used in the management schizophrenia 
and mania in adults possess isoxazole moiety
12
. Some 
of the marketed drugs possessing isoxazole scaffold 
such as Cycloserine, Sulphamethoxazole, Oxacillin, 
Cloxacillin and dicloxacillin (Figure 1) are used in the 
treatment of microbial infections. Muscimol
13
 and 
mofezolac are used as sedatives. In addition, various 
drugs used against different diseases were found to 
contain this medicinally important scaffold. 
Isoxazole is an integral part of a powerful 
antifungal drug, Micafungin
14
 (Figure 2) available in 
the market. Therefore, this area of research signifies a 
challenging and demanding problem which should be 
tackled by discovering new antifungal drugs. 
In this context, Santos and co-workers reported 
new isoxazole compounds with good antifungal 
activity than the standard Amphotericin B drug with 
MIC ranging from value of 0.2-47.9 μg/mL against 
Candida parapsilosis and Candida glabrata, 
respectively
15
. Later, Srinivas and co-workers 
prepared a new class of thiazolidinone clubbed 
isoxazole derivatives
16
. Out of which, some 
compounds demonstrated equipotent antifungal 
activity with the reference drug Amphotericin B 
against the tested fungi and surfaced as shows 
potential molecules for additional development. 
On the other hand, Benzothiazole is the bicyclic 
fused ring, which contain benzene and heterocyclic 
five membered thiazole ring, while the core structure 
of thiazole and it’s pharmacologically and 
biologically active properties are due to the presence 
of sulfur and nitrogen atoms present in the ring 
chemistry. Benzothiazoles are known to exhibit 
diverse biological activities viz. antiproliferative, 
antibacterial, anticonvulsant, antiretroviral, antimyco-
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bacterial, antiparasitic, analgesic, antiinflammtory, 
antidiabetic as well as fungicidal activities
17-21
. 
Although abundant efforts have been made to 
develop new arsenal of antifungal antibiotics, 
Benzothiazole (BTA) derivatives appear as one of the 
most therapeutic versatile antimicrobial compounds
22
 
and therefore, are constructive motif for exploring newer 
antimicrobials. Literature review has revealed that there 
is a significant potential for BTA derivatives in 
discovering newer agents to combat multidrug resistance. 
Consequently, pyrazolinone/linked Benzo- 
thiazoles having antibacterial property against a range 
of tested organisms have been reported by Amir and 
co-workers. The prepared BTA-pyrazoline 
compounds bearing halogen groups at para position 
of the benzene ring displayed good to considerable 
anti-bacterial activities in the MIC range of 13.95-
31.01 μM, respectively Figure 2 (I a-c). However, 
compounds with methyl group in the same position 
displayed decreased activity. Similar trend in anti-
bacterial activity was observed in case of BTA-
pyrazoles conjugates, compound (II,a-b)
23
 (Figure 2). 
Overall, 6-chloroBenzothiazole groupwas found to be 
favorable for activity These compounds were also 
screened for antifungal activity against various tested 
fungi and the results revealed that these compounds 
exhibited promising antifungal activities, particularly, 
compounds (III, a,b) (Figure 2). SAR suggested that 
2-mercapto derivatives were normally more active 
against bacteria, while the 2-amino ones were more 
potent against fungi. This highlights that enhanced 
antifungal activity can be achieved by incorporating 
bulky groups at the 6-position of the 2-
aminobenzothiazole moiety. 
Results and Discussion 
Chemistry 
The Synthesis of Benzothiazole linked Isoxazole 
Schiff bases 12a-p was carried out by condensation 
Figure 1 — Structures of Isoxazole containing drugs 
Figure 2 — Benzothiazole derivatives exhibiting antimicrobial 
activity 
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between an equivalent quantity of substituted 2-amino 
benzothiazole and 2-substituted 3-phenyl-1H- 
isoxazol-5-carbaldehyde 11a-d in ethanol
24
, as 
depicted in Scheme I. Isoxazole carbaldehydes 11a-d 
were prepared initially by cyclizing substituted 
acetophenone 7a-d with diethyl oxalate in the 
presence of newly prepared sodium ethanolate in 
ethanol to obtain diketo esters 8a-d which were then 
cyclized with NH2-NH2.2HCl to yield ethyl 
3-substituted phenyl-1H-isoxazol-5-carboxylates 
9a-d in good yields. The reduction of these 
carboxylates by LiAlH4 furnished the corresponding 
alcohols 10a-d which were selectively oxidized to 






Minimum inhibitory concentration (MIC) 
The prepared compounds were investigated for their 
in vitro antimicrobial activity using well diffusion 
method
26
 against a panel of Gram-positive and Gram-
negative bacterial strains along with a fungal strain, 
Candida albicans. Ciprofloxacin (CPZ) and 
Miconazole (MCZ) were used as drugs (Controls). Out 
of all the tested compounds, compounds 12d, 12g, and 
12l showed appreciable activities towards all the 
bacterial strains with MIC values ranging between 
3.9-32.5 µg/mL, respectively as illustrated in Table I. 
Interestingly, 12d, 12g, and 12l exhibited promising 
antifungal activity with MIC values ranging between 
7.8 -31.2 µg/mL, respectively. 
Minimum bactericidal concentration and Minimum 
Fungicidal concentration (MBC/MFC) 
All the prepared compounds were screened for their 
Minimum bactericidal concentration Minimum 
Fungicidal concentration (MBC/MFC)
27
. Among them, 
compounds 12d, 12g, and 12l demonstrated superior 
activities towards all the tested strains with MBC/MFC 
values ranging between 7.8 -31.2 µg/mL as mentioned 
in Table II. 
Experimental Section 
Chemistry 
Preparation of ethyl 2,4-dioxo-4-(substituted phenyl) 
butanoates,8a-d 
Initially sodium ethanolate was prepared in situ and 
diethyl oxalate (1.0 mol) was added slowly at 0°C. 
The stirring was continued for 15 minutes followed 
by the addition of different acetophenones 7a-d 
(1.0 mol) slowly in small portions, maintaining the 
temperature at 0°C. After completion of addition, the 
stirring was continued for 4 h at RT. The progress of 
Scheme I — Synthesis of Benzothizole linked Isoxazole Schiff bases 12a-p 




the reaction was monitored by TLC using ethyl 
acetate and hexane as the mobile phase. After 
completion of reaction, the reaction mixture was 
neutralized using dilute H2SO4 solution and further 
extracted with ethyl acetate followed by evaporation 
of the solvent under reduced pressure to obtain solid 
products 8a-d in good yields (80–90%). These were 
taken as such for the next step without purification. 
 
Preparation of ethyl 3-substituted isoxazole-5-
carboxylates, 9a-d 
To each of the ethyl 2,4-dioxo-4-(substituted 
phenyl)butanoates 8a-d (1.0 mol) prepared in the 
previous step was added hydroxylamine hydrochloride 
(NH2OH•HCl) (1.5 mol) in ethanol and refluxed for  
3–4h. After completion of the reaction, the ethanol was 
removed under reduced pressure and then 150–200 mL 
of water was added to the residue followed by 
extraction with ethyl acetate (50 mL × 4). The organic 
layer was dried on anhydrous Na2SO4 and solvent was 
removed to obtain a crude compound that was further 
purified by column chromatography using an ethyl 
acetate and hexane solvent system (3:7). The pure 
compounds 9(a–d) were eluted with 30–40% of ethyl 
acetate in hexane with good yields. 
 
9a: Yellow colored solid. Yield 80.0%. Rf = 0.3 
(30% ethyl acetate/ hexane); 
1
H NMR (300 MHz, 
CDCl3); δ 1.23-1.37 (t, 3H, J1= 6.7 Hz, J2 =7.5 Hz), 
3.81 (s, 3H), 4.17-4.36 (q, 2H, J1 = 6.7 Hz, J2 = 7.5 
Hz), 6.84 (s, 1H), 6.90 (d, 2H, J =2.2 Hz), 7.62 (d, 2H, 
J= 9.0 Hz); MS (ESI): m/z 248 [M +H]. 
 
9b: Pale yellow colored solid. Yield 80.0%. Rf = 0.3 
(30% ethyl acetate/hexane); 
1
H NMR (300 MHz, 
CDCl3); δ 1.23-1.31 (t, 3H, J = 7.1 Hz), 3.85 (s, 3H), 
3.90 (s, 3H), 4.19- 4.32 (q, 2H, J1 =.1 Hz), 6.88 (d, 1H, 
J=7.1 Hz), 6.94 (s, 1H), 7.21-7.28 (m, 1H), 7.29-7.34 
(m, 1H); MS (ESI): m/z 278 [M + H]. 
 
9c: Pale yellow colored solid. Yield 75.0%. Rf = 0.3 
(40% ethyl acetate/hexane); 
1
H NMR (500 MHz, 
CDCl3); δ 1.33-1.40 (t, 3H, J1 = 6.7 Hz, J2 = 7.5 Hz,), 
4.33-4.45 (q, 2H, J1 = 6.7 Hz, J2 =7.5 Hz), 6.0 (s, 2H), 
6.86 (d, 1H, J ¼ 8.3 Hz), 7.05 (s, 1H), 7.21-7.28 (m, 
2H); MS (ESI): m/z 262 [M + H]. 
 
9d: Yellow colored solid. Yield 75.0%. Rf = 0.3 
(40% ethyl acetate/ hexane); 
1
H NMR (300 MHz, 
CDCl3); δ 1.33-1.40 (t, 3H, J1= 6.7 Hz, J2 = 7.5 Hz), 
3.88 (s, 3H), 3.95 (s, 6H), 4.33-4.45 (q, 2H, J1 =6.7 
Hz, J2= 7.5 Hz), 7.01 (s, 2H), 7.05 (s, 1H); MS (ESI): 
m/z 308 [M + H]. 
 
Preparation of (3-substitutedphenyl-isoxazole-5-yl) 
methanols, 10a-d 
To the ethyl 3-substituted isoxazole-5-carboxylates 
9a-d, obtained in the above step was added LiAH4  
(0.5 mol) in dry THF at 0°C and stirred for 1h at RT. 
Added saturated NH4Cl solution drop wise to quench the 
unreacted LiAlH4 and removed the THF under vacuum 
Table I — Antimicrobial activity of the synthesized compounds 
Compd  Minimum inhibitory concentration (µg/mL) 
















12a ˃125 ˃125 ˃125 ˃125 7.8 ˃125 ˃125 ˃125 ˃125 
12b ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12c ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12d 15.6 3.9 3.9 7.8 3.9 3.9 7.8 ˃125 7.8 
12e 15.6 3.9 ˃125 15.6 3.9 3.9 7.8 ˃125 31.2 
12f ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12g ˃125 ˃125 ˃125 3.9 7.8 ˃125 3.9 ˃125 7.8 
12h ˃125 ˃125 ˃125 ˃125 3.9 3.9 ˃125 ˃125 ˃125 
12i 7.8 ˃125 ˃125 15.6 3.9 3.9 15.6 ˃125 ˃125 
12j 15.6 ˃125 ˃125 15.1 ˃125 ˃125 ˃125 ˃125 15.6 
12k 15.6 3.9 3.9 7.8 3.9 7.8 7.8 7.8 15.6 
12l 15.6 3.9 ˃125 7.8 ˃125 3.9 15.6 3.9 7.8 
12m ˃125 3.9 ˃125 7.8 3.9 7.8 15.6 15.6 31.2 
12n 3.9 7.8 ˃125 ˃125 3.9 ˃125 7.8 15.6 31.2 
12o 15.6 7.8 15.6 7.8 15.6 7.8 ˃125 ˃125 15.6 
12p 7.8 7.8 15.6 7.8 15.6 15.6 ˃125 ˃125 31.2 
Miconazole − − − − − − − − 3.9 
Ciprofloxacin 0.9 0.9 0.9 0.9 0.9 0.9 0.9 − − 




then extracted with ethyl acetate (100 mL × 4). The 
organic layer was dried on anhydrous Na2SO4 and 
evaporated ethyl acetate to obtain colorless solid 
products of (3-substitutedphenyl-1H-pyrazol-5-yl) 
methanols10a-d in 70-80% yield. The alcohols 
produced in this step were pure, and no further 
purification was required. These compounds were taken 




To the (3-substitutedphenyl-1H-pyrazol-5-yl) 
methanols 10a-d produced in the above step was added 
IBX (1.2 mol) in DMSO and stirred for 1h at RT. 
Added ice cold water to the reaction mixture and 
extracted with ethyl acetate (50 mL × 4). The organic 
layer was dried on anhydrous Na2SO4 and evaporated 
the ethyl acetate to obtain pure corresponding 3-
subtitutedphenyl-1H-pyrazole- 5-carbaldehydes 11a-d 
in good yields (80-85%). The obtained carbaldehydes 
were as such taken in the next step for the synthesis of 
pyrazoleoxindole conjugates 12a-p. 
 
11a: Yellow colored solid. 1.71 g, yield 85%.  
Rf = 0.3 (40% ethyl acetate/hexane); 
1
H NMR  
(400 MHz, CDCl3); δ 3.85 (s, 3H,), 7.78-7.82 (m, 1H), 
7.86-7.93 (m, 2H), 7.95-8.03 (m, 2H), 9.95 (s, 1H); MS 
(ESI): m/z 204 [M + H]. 
 
11b: Yellow colored solid. 1.85 g, yield 82%.  
Rf = 0.4 (40% ethyl acetate/hexane); 
1
H NMR (300 
MHz, CDCl3); δ 3.87 (s, 3H), 3.91 (s, 3H), 6.93-7.04 
(m, 1H), 7.27-7.47 (m, 2H), 7.86-8.10 (m, 1H), 9.93  
(s, 1H); MS (ESI): m/z 234 [M + H]. 
 
11c: Yellow colored solid. 2.09 g, yield 80%.  
Rf = 0.3 (40% ethyl acetate/hexane); 
1
H NMR (400 
MHz, CDCl3); δ 3.82 (s, 3H), 3.92 (s, 6H), 6.85-7.25 
(m, 3H,), 9.96 (s, 1H); MS (ESI): m/z 264 [M + H]. 
 
11d: Yellow colored solid. 1.83 g, yield 85%.  
Rf = 0.3 (40% ethyl acetate/hexane); 
1
H NMR (300 
MHz, CDCl3): δ d 6.03 (s, 2H), 7.35e7.45 (m, 1H), 
7.87-7.94 (m, 2H), 8.10-8.17 (m, 1H), 10.2 (s, 1H); MS 
(ESI): m/z 219 [M +H]. 
 
General procedure for the synthesis of Benzothizole 
linked Isoxazole Schiff bases, 12a-p 
Initially, equimolar quantities of substituted 
isoxazole carboxaldehydes (1.0 eq) and appropriate 
amino benzothiazoles (1.0 eq) were dissolved in 
absolute ethanol (6 mL) and the reaction was refluxed 
for 3-4 h. The progress of the reaction was monitored 
by TLC using ethyl acetate and hexane (1: 1) solvent 
system. Then the reaction was cooled to obtain the 
solid precipitate. The precipitate was filtered off, 
washed with ice cold water and recrystallized in small 
quantity of absolute ethanol to furnish the titled 
compounds 12a-p in good to excellent yields. 
 
Spectral Data 
12a: Yellow solid. 81.5% yield; m.p. 184-185°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.81 (s, 6H), 3.84  
Table II — Minimum bactericidal concentration Minimum Fungicidal concentration (MBC/MFC) (µg/mL) the synthesized compounds 

















12a ˃125 ˃125 ˃125 ˃125 15.6 ˃125 ˃125 ˃125 ˃125 
12b ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12c ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12d 31.2 7.8 7.8 15.6 7.8 7.8 15.6 ˃125 15.6 
12e 31.2 7.8 ˃125 31.2 7.8 7.8 15.6 ˃125 62.5 
12f ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 ˃125 
12g ˃125 ˃125 ˃125 7.8 15.6 ˃125 7.8 ˃125 15.6 
12h ˃125 ˃125 ˃125 ˃125 7.8 7.8 ˃125 ˃125 ˃125 
12i 15.6 ˃125 ˃125 31.2 7.8 7.8 31.2 ˃125 ˃125 
12j 31.2 ˃125 ˃125 31.2 ˃125 ˃125 ˃125 ˃125 31.2 
12k 31.2 7.8 7.8 15.6 7.8 15.6 15.6 15.6 31.2 
12l 31.2 7.8 ˃125 15.6 ˃125 7.8 31.2 7.8 15.6 
12m ˃125 7.8 ˃125 15.6 7.8 15.6 15.6 31.2 62.5 
12n 7.8 15.6 ˃125 ˃125 7.8 ˃125 15.6 62.5 62.5 
12o 31.2 15.6 31.2 15.6 31.2 15.6 ˃125 ˃125 31.2 
12p 15.6 15.6 31.2 15.6 31.2 31.2 ˃125 ˃125 62.5 
Miconazole − − − − − − − − 7.8 
Ciprofloxacin 0.9 0.9 0.9 0.9 0.9 0.9 0.9 − − 
 




(s, 3H), 6.76 (s, 1H), 6.85 (d, J = 8.3 Hz,1H), 6.88 (d, J 
= 8.8 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.30 -7.35  
(m, 2H), 7.54 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.4 Hz, 
1H); 
13
C NMR (125 MHz, CDCl3+DMSO-d6): δ 55.5, 
60.0, 100.9, 101.0, 102.3, 109.6, 109.7, 137.3, 152.9, 
157.6, 159.5; MS (ESI): m/z 395. 
 
12b: Yellow solid. 72.6% yield; m.p. 164-166°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 (s, 6H), 6.93  
(d, J = 8.1 Hz,1H), 7.02 (s, 1H), 7.35 (d, J = 8.4 Hz, 
2H), 7.71 (dd, J = 8.4 Hz and 8.4 Hz, 3H), 8.26 (s, 1H); 
13
C NMR (125 MHz, CDCl3+DMSO-d6): δ 54.7, 55.0, 
99.8, 111.0, 113.7, 126.2, 127.4, 129.9, 131.7, 131.5, 
155.5, 158.9; MS (ESI): m/z 383. 
 
12c: Yellow solid. 71.5% yield; m.p. 142-143°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.73 (s, 6H), 6.93  
(d, J = 8.2 Hz,1H), 7.00 (s, 1H), 7.09 (d, J= 7.9 Hz, 1H), 
7.35 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.8 Hz, 1H), 7.71 (d, 
J = 7.7 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H); 
13
C NMR (125 
MHz, CDCl3+ DMSO-d6): δ 55.3, 55.4, 100.7, 108.6, 
111.7, 117.7, 124.6, 148.6; MS (ESI): m/z 418. 
 
12d: Yellow solid. 71.0% yield; m.p. 169-170°C; 
1
H NMR (300 MHz, DMSO-d6): δ 2.35 (s, 3H), 3.73  
(s, 6H), 6.93 (d, J = 9.0 Hz, 1H), 7.00 (s, 1H), 7.03 (d, J 
= 8.3 Hz, 1H), 7.13-7.23 (m, 1H), 7.34 (s, 2H),  
7.44-7.53 (m, 1H), 7.56 (d, J = 8.3 Hz, 1H); 
13
C NMR 
(125 MHz, , CDCl3+ DMSO-d6): δ 28.8, 54.7, 100.3, 
113.9, 121.7, 126.3, 159.0; MS (ESI): m/z 379. 
 
12e: Yellow solid. 61.5% yield; m.p. 154 – 186°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.77 (s, 3H),  
6.95-6.98 (m, 1H), 7.02 (d, J = 8.3 Hz, 2H), 7.13-7.18 
(m, 1H), 7.25-7.43 (m, 1H), 7.56-7.66 (m, 1H), 7.76  
(t, J = 8.4 and 9.1 Hz, 2H), 8.25 (s, 1H); 
13
C NMR  
(125 MHz, CDCl3 + DMSO-d6): δ 54.6, 100.1, 113.7, 
121.4, 126.2, 159.8; MS (ESI): m/z 352. 
 
12f: Yellow solid. 69.8% yield; m.p. 174-175°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.75 (s, 6H), 6.94 (d, 
J = 8.1 Hz,1H), 7.01 (s, 1H), 7.11 (d, J = 8.0 Hz, 1H), 
7.37 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.4 Hz, 1H), 7.73 
(d, J = 7.9 Hz, 1H), 7.82 (s, 1H); 
13
C NMR (125 MHz, 
CDCl3 + DMSO-d6): δ 54.9, 55.5, 103.2, 108.7, 127.9, 
128.0, 130.7, 131.5, 138.0, 139.1, 149.8, 159.8; MS 
(ESI): m/z 433. 
 
12g: Yellow solid. 71.9% yield; m.p. 170 – 172°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.76 (s, 6H), 6.91  
(s, 1H), 6.99 (d, J = 6.7 Hz, 1H), 7.09-7.20 (m, 1H), 7.33 
(d, J = 5.8 Hz, 3H), 7.55-7.63 (m, 2H), 8.20 (s, 1H); 
13
C NMR (125 MHz, CDCl3+ DMSO-d6): δ 54.9, 59.9, 
102.3, 113.3, 121.7, 130.1, 137.2, 152.8; MS (ESI)  
m/z: 365. 
12h:Yellow solid. 82.5% yield; m.p. 189 – 192°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.77 (s, 3H), 6.90  
(s, 2H), 7.16 (s, 1H), 7.40 (s, 1H), 7.54-7.68 (m, 2H), 
7.72 (d, J = 8.3 Hz, 2H), 8.25 (s, 1H);
 13
C NMR  
(125 MHz, CDCl3+DMSO-d6): δ 54.8, 100.3, 109.4, 
109.7, 113.9, 126.4, 130.2, 136.5, 136.6, 156.9, 159.1, 
160.0; MS (ESI): m/z 369. 
 
12i: Yellow solid. 82.1% yield; m.p. 164 – 165°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.74 (s, 3H), 6.03  
(s, 2H), 6.74 (d, J = 8.1, 2H), 7.10 (s, 1H), 7.29  
(d, J = 8.2 1 Hz, 2H), 7.94 (d, J = 8.1Hz, 2H), 8.28 (s, 
1H); 
13
C NMR (125 MHz, DMSO-d6): δ 56.7, 100.0, 
105.8, 112.2, 128.4, 130.3, 130.7, 133.5, 136.2, 138.2, 
139.1, 149.8, 158.8; MS (ESI): m/z 368. 
 
12j: Yellow solid. 73.5% yield; m.p. 168 – 170°C; 
1
H NMR (300 MHz, DMSO-d6): δ 6.04 (s, 2H),  
6.74-6.79 (m, 2H), 7.06 (s, 1H), 7.29 (t, J = 8.8 and 10.1 
Hz, 2H), 7.90 (d, J = 8.4Hz, 2H), 8.26 (s, 1H); 
13
C NMR 
(125 MHz, CDCl3+DMSO-d6): δ 100.4, 100.7, 105.4, 
108.1, 118.8, 147.0, 147.5; MS (ESI): m/z 367. 
 
12k: Yellow solid. 71.8% yield; m.p. 187 – 189°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 (s, 6H), 3.73  
(s, 3H), 3.75 (s, 3H), 6.93 (s, 1H), 6.97 (d, J = 7.7 Hz, 
3H), 7.23 (d, J = 6.8 Hz, 2H), 8.21 (s, 1H); 
13
C NMR 
(125 MHz, CDCl3 + DMSO-d6): δ 56.3, 60.4, 102.2, 
108.9, 113.7, 116.2, 124.3, 126.2, 130.3, 131.5, 132.1, 
136.8, 149.8, 158.8; MS (ESI): m/z 425. 
 
12l: Yellow solid. 83.8% yield; m.p. 174 – 177°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.80 (s, 3H), 3.86 (s, 
6H), 6.79 (s, 1H), 6.86 (s, 1H), 7.09 (t, J = 8.1and 8.8 
Hz, 1H), 7.30 (s, 1H), 7.63 (t, J = 7.5 and 8.1 Hz, 2H), 
7.80 (s, 1H); 
13
C NMR (125 MHz, DMSO-d6): δ 55.5, 
60.0, 100.9, 102.2, 121.6, 137.2, 152.9; MS (ESI): m/z 
413. 
 
12m: Yellow solid. 77.3% yield; m.p. 184 – 185°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.73 (s, 6H), 3.75 (s, 
3H), 3.77 (s, 3H), 6.95 (s, 1H), 6.98 (d, J = 8.0 Hz, 3H), 
7.25 (d, J = 7.8 Hz, 2H), 8.22 (s, 1H); 
13
C NMR (125 
MHz, DMSO-d6): δ 53.2, 55.8, 60.4, 103.2, 109.6, 
116.2, 120.1, 124.5, 126.9, 128.3, 132.6, 135.2, 140.1, 
149.8, 157.8; MS (ESI): m/z 425. 
 
12n: Yellow solid. 81.5% yield; m.p. 184 – 185°C; 
1
H NMR (300 MHz, DMSO-d6): δ 3.78 (s, 3H), 3.84  
(s, 6H), 6.81 (s, 1H), 6.84 (s, 2H), 7.09 (t, J = 8.0 and 8.2 
Hz, 2H), 7.39 (s, 1H), 7.82 (s, 1H); 
13
C NMR (125 MHz, 
DMSO-d6): δ 54.5, 55.6, 106.2, 111.7, 119.2, 126.3, 
128.9, 131.7, 134.2, 135.0, 138.1, 149.8, 158.8; MS 
(ESI): m/z 431. 




12o:White solid. 71.1% yield; m.p. 169 – 172°C; 
1
H NMR (300 MHz, DMSO-d6): δ 6.03 (s, 2H),  
6.76-6.81 (m, 2H), 7.04 (s, 1H), 7.32 (d, J = 8.8 Hz, 
2H), 7.93 (d, J = 8.1Hz, 2H), 8.24 (s, 1H); 
13
C NMR 
(125 MHz, DMSO-d6): δ 100.1, 108.7, 113.3, 122.8, 
127.3, 128.0, 131.7, 135.3, 138.1, 149.8, 160.1;MS 
(ESI):m/z 385. 
 
12p:Yellow solid. 81.8% yield; m.p. 190 – 192°C; 
1
H NMR (300 MHz, DMSO-d6): δ 6.08 (s, 2H), 6.76 
(d, J = 8.4 Hz, 2H), 7.08 (s, 1H), 7.39 (d, J = 8.1 Hz, 
2H), 7.90 (d, J = 8.4 Hz, 2H), 8.28 (s, 1H); 
13
C NMR 
(125 MHz, DMSO-d6): δ 99.2, 106.7, 111.4, 120.3, 






The antimicrobial activity of the synthesized hybrids 
was evaluated using well diffusion method against 
various pathogenic Gram positive and Gram negative 
bacterial strains and different Candida strains procured 
from Microbial Type Culture Collection and Gene Bank 
(MTCC), CSIR-Institute of Microbial Technology, 
Chandigarh, India. Previously activated pathogenic 
strains including Bacillus subtilis MTCC 121, 
Staphylococcus aureus MLS-16 MTCC 2940, 
Micrococcus luteus MTCC 2470, Staphylococcus 
aureus MTCC 96, Escherichia coli MTCC 739, 
Pseudomonas aeruginosa MTCC 2453, Klebsiella 
planticola MTCC 530, Candida albicans MTCC 3017 
containing 1.5 × 10
8 
cfu/mL (equal to 0.5 McFarland 
standard) were spread onto the surface of Mueller-
Hinton agar plates using sterile cotton swabs. 
Afterwards in the agar plates, wells of 6 mm diameter 
were prepared using a cork borer and the compounds 
with different concentration (ranging from 125-0.97 
µg/mL) prepared in DMSO (10%) were loaded in each 
well. Further, DMSO (negative control), ciprofloxacin 
and miconazole (positive controls) (ranging from 125-
0.97 µg/mL) were run in parallel. Plates were thereafter 
incubated at 37°C for 24 h. All the experiments were 
conducted in triplicates and represented as mean values. 
 
Minimum Bactericidal Concentration and Minimum 
Fungicidal concentration (MBC/MFC) 
The effect of various synthesized derivatives on the 
viability of various strains was determined in terms of 
minimum inhibitory concentration (MIC) and 
minimum fungicidal concentration (MFC). The 
fungicidal assay was performed in sterile 2.0 mL 
microfuge tubes against a panel of different pathogenic 
strains which were cultured overnight in Mueller 
Hinton broth. MFC is the lowest concentration of 
compound required to kill a particular Candida strain 
under the above assay conditions. All the experiments 




To recapitulate, a new series of benzothiazole linked 
isoxazole Schiff base derivatives were synthesized and 
characterized by suitable spectra and were investigated 
for antimicrobial activity against a panel of pathogenic 
microorganisms. Among them, compounds 12d,12g 
and 12l were found to be prime candidates because of 
their promising antimicrobial activity against all the 
tested strains with MIC values ranging between  
3.9 – 62.5 µg/mL. Further, compounds 12d, 12g, and 
12l exhibited promising antifungal activity with MIC 
values ranging between 7.8 - 32.5 µg/mL. These three 
leads could be considered as prime candidates for 








1 Levy SB& MarshallB, Nat Med, 10 (2004) S122. 
2 Garibotto F M, Garro A D, Masman M F, Rodriguez A M, 
Luiten P G, Raimondi M M, Zacchino S A, Somlai C, Penke 
B&Enriz R D, Bioorg Med Chem, 18 (2010) 158. 
3 Brown G D, Denning D W & Levitz S M, Science, 336 
(2012) 647. 
4 Agrawal N & Mishra P, Med Chem Res, 27 (2018) 1309. 
5 Zhu J, Mo J, Lin H Z, Chen Y & Sun H P, Bioorg Med 
Chem, 26 (2018) 3065. 
6 Anand P & Singh B, Mini Rev Med Chem, 14 (2014) 623. 
7 Barmade M A, Murumkar P R, Sharma M K & Yadav M R, 
Curr Top Med Chem, 16 (2016) 2863. 
8 Sysak A & Obminska-Mrukowicz B, Eur J Med Chem, 137 
(2017) 292. 
9 Shaik A, Bhandare RR, Palleapati K, Nissankararao S, 
Kancharlapalli V, Shaik S, Molecules, 25 (2020) 1047. 
10 Mukhopadhyay S, Barak DS, Karthik R, Verma SK, Bhatta 
RS, Goyal N & Batra S, RSC Med Chem, 11 (2020) 1053. 
11 Shi W, Hu J, Bao N,Li D,Chen L & JSun, Bioorg Med Chem 
Lett, 27 (2017) 147. 
12 Noto MN, Maes M, Vargas Nunes SO, Ota VK, Cavalcante 
D, Oliveira G, Rossaneis AC, Verri WA Jr, Cordeiro Q, 
Belangero SI, Gadelha A, Noto C & Bressan RA, J Psychiatr 
Res, 141 (2021) 206. 
13 Johnston & Graham A R, Neurochemical Res, 39 
(2014)1942. 
14 Hashimoto S, J Antibiotics, 62 (2009) 2. 




15 Santos MMM, Faria N,Iley J,Coles S J, Hursthouse M B, 
Martins M L & Moreira R,Bioorg Med Chem Lett, 20  
(2010) 193. 
16 Srinivas A, Nagaraj A & Reddy C S, Eur J Med Chem, 45 
(2010) 2353. 
17 Keri R S, Patil M R, Patil S A & Budagumpi S, Eur J Med 
Chem, 89 (2015) 207. 
18 Banerjee S, Payra S & Saha, Curr Organocatal, 4 (2017) 164. 
19 Irfan A, Batool F, Zahra Naqvi S A, Islam A, Osman S M, 
Nocentini A, Alissa S A & Supuran C T, J Enzyme Inhib 
Med Chem, 35 (2020) 265. 
20 Luo B, Li D, Zhang A L & Gao J M, Molecules, 23 (2018) 
2457. 
21 Singh M, Singh S K, Gangwar M, Nath G & Singh S K, RSC 
Adv, 4 (2014) 19013. 
22 Amir M, Javed S A & Hassan MZ, Med Chem Res, 21 
(2012) 1261. 
23 Catalano A, Carocci A, Defrenza I, Muraglia M, Carrieri A, 
Bambeke F V, Rosato A, Corbo F & Franchini C, Eur J Med 
Chem, 64 (2013) 357. 
24 Shareef M A, Sirisha K, Khan I, Sayeed I B, Jadav S, Ramu 
G, Kumar C G, Kamal A & Babu B N, Medchemcomm, 10 
(2019) 806. 
25 Khan I, Kanugala S, Shareef M A, Ganapathi T, Shaik A B, 
Shekar K C, Kamal A & Kumar C G, Chem Biol Drug Des, 
94 (2019) 1339. 
26 Amsterdam D, ‘Susceptibility testing of antimicrobials in 
liquid media’,inAntibiotics in Laboratory Medicine, 4th Edn, 
edited by V Loman (Williams and Wilkins, Baltimore, MD), 
pp.52–111 (1996). 
27 CLSI (2017) Reference method for broth dilution antifungal 
susceptibility testing of yeasts. Approved standard. 
Document M27, 4th Edn, Clinical and Laboratory Standards 
Institute, Wayne, PA. 
 
